FDA warned Cholrem over selling unapproved RemChol enema products with claims to treat atherosclerosis and reverse heart disease.
What happened
In May 2024, FDA reviewed Cholrem’s websites and social media pages and found the company offering RemChol, RemChol Saver Set, RemChol Starter Pack, and RemChol Ultra Set for sale in the United States. The pages claimed these products treat atherosclerosis, reverse heart disease, reduce plaque, lower cholesterol, and provide other disease benefits. FDA concluded the products are unapproved new drugs.
What FDA found
FDA treated RemChol and Cavadex/Cavadextrin as drugs because the websites and social media said they diagnose, cure, mitigate, treat, or prevent disease or affect body structure or function.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)FDA said the products are not generally recognized as safe and effective for those uses, so they are new drugs.
FD&C Act section 201(p), 21 U.S.C. 321(p)FDA said no approved application is in effect for the products, so selling them in U.S. interstate commerce violates the FD&C Act.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA asks Cholrem to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with supporting documents. If correction cannot be completed in that time, the company must explain the delay and give a completion date.
Who should pay attention
- sellers of enema or cyclodextrin products with disease claims
- companies that market online and through social media in the U.S.
- quality and regulatory teams reviewing consumer product claims
This is a summary. Read the original letter on fda.gov.